Menu
NASP

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Optimizing Hepatitis C Disease Management: Implications for Specialty Pharmacy

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE) 

 
 View more NASP/CSPE Activities
 

NOTE: If you attended the live CE activity titled "Optimizing Hepatitis C Disease Management: Implications for Specialty Pharmacy" that was held on September 20, 2017 during the 2017 NASP Annual Meeting and Educational Conference in Washington, DC AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-0000-17-348-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.

HCV remains a highly prevalent, extremely costly disease. Specialty pharmacists have a significant role in helping HCV patients achieve individualized treatment goals. This CE activity will present strategies to support treatment adherence, navigate cost issues, manage special populations, and ensure optimal patient outcomes.

Learning Objectives

The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:

  • Discuss the epidemiology and pathophysiology of hepatitis C virus (HCV) infection
  • Identify the clinical benefits of individualized patient management that stem from new and emerging HCV agents and treatment algorithms
  • Examine the cost associations of HCV treatment options against the cost of disease and standard therapies to support individualized therapy selection and patient management
  • Describe the role of the specialty pharmacist in patient education and adherence to HCV treatment

Faculty

Speaker: Linda Spooner, PharmD, RPh, BCPS (AQ-ID), FASHP, FCCP
Professor of Pharmacy Practice
Department of Pharmacy Practice
MCPHS University (Massachusetts College of Pharmacy and Health Sciences)
Worcester, Massachusetts

Moderator: Alicia B. Carver, PharmD, BCPS, CSP
Clinical Pharmacist
Specialty Pharmacy Services
Vanderbilt University Medical Center
Nashville, Tennessee

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Carver has no relevant commercial or financial relationships to disclose. Dr. Spooner has no relevant commercial or financial relationships to disclose.

The opinions expressed in this activity should not be construed as those of the CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

CE Accreditation

Release Date: 9-20-2017
Expiration Date: 12-31-2018

Pharmacists

ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-17-348-H01-P has been assigned to this knowledge-based home-study CE activity (initial release date 9-20-17). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.

Funding

This CE activity is supported by an educational grant from Merck & Co., Inc.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.